I can't comment on what might happen in the long run, simply because I don't know. For now, though, the possibility of any big pharma, willing to partner, seems unlikely. Many Alzheimer's drug candidates, show promise early on, nearly all are unsuccessful. This stock has been plagued by typical "pump and dump" tactics which have been going on since the stock left penny land. Run the stock up on wild assertions of partner coming soon, $50 after results, Etc. Sell on or near the news, steal the suckers money. A scam as old as the hills and very prevalent in small biotech's about to report results.
Some where down the road, there may be facts to back up a partner or accelerated treatment by the FDA. In the short run, I don't see anything that would rise to that level. Other that a bit of "day dreaming"